{"version":"1.0","type":"link","title":"Intentional internal high-dose policy in VMAT for stage III NSCLC with consolidation durvalumab - a retrospective study.","author_name":"Okuma K 외","author_url":"https://prs-insight.online/author/Okuma%20K","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/96755","thumbnail_width":1200,"thumbnail_height":630}